Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
![Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy - Vimarsana News](https://cdn.sanity.io/images/0vv8moc6/ajmc/a6379ae5a3195e91de6296119ab43ff693d85a9b-1920x1080.png?fit=crop&auto=format)
A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed as a distinctive therapy for Hypertrophic Cardiomyopathy.
Last year, the Governor signed into law a bill extending the application of the Public Employer Workplace Violence Prevention Act (the Act) to school districts and BOCES. The law went...
The FDA is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking drugs like Ozempic, Mounjaro and Wegovy.
The US Food and Drug Administration is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking medications like Ozempic, Mounjaro and Wegovy.